206 related articles for article (PubMed ID: 15492256)
1. Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1.
Kim IY; Lee DH; Lee DK; Kim WJ; Kim MM; Morton RA; Lerner SP; Kim SJ
Cancer Res; 2004 Oct; 64(20):7355-60. PubMed ID: 15492256
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells.
Kim IY; Lee DH; Lee DK; Kim BC; Kim HT; Leach FS; Linehan WM; Morton RA; Kim SJ
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6046-51. PubMed ID: 14676131
[TBL] [Abstract][Full Text] [Related]
3. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells.
Kim IY; Lee DH; Lee DK; Ahn HJ; Kim MM; Kim SJ; Morton RA
Oncogene; 2004 Oct; 23(46):7651-9. PubMed ID: 15354178
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2.
Chaffer CL; Brennan JP; Slavin JL; Blick T; Thompson EW; Williams ED
Cancer Res; 2006 Dec; 66(23):11271-8. PubMed ID: 17145872
[TBL] [Abstract][Full Text] [Related]
5. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
Shen SS; Smith CL; Hsieh JT; Yu J; Kim IY; Jian W; Sonpavde G; Ayala GE; Younes M; Lerner SP
Cancer; 2006 Jun; 106(12):2610-6. PubMed ID: 16700038
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients.
Tokunaga H; Lee DH; Kim IY; Wheeler TM; Lerner SP
Clin Cancer Res; 1999 Sep; 5(9):2520-5. PubMed ID: 10499628
[TBL] [Abstract][Full Text] [Related]
7. Role of bone morphogenetic proteins in transitional cell carcinoma cells.
Kim IY; Kim SJ
Cancer Lett; 2006 Sep; 241(1):118-23. PubMed ID: 16500023
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma.
Messing EM
Cancer Res; 1990 Apr; 50(8):2530-7. PubMed ID: 1690599
[TBL] [Abstract][Full Text] [Related]
9. Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues.
Kim IY; Lee DH; Ahn HJ; Tokunaga H; Song W; Devereaux LM; Jin D; Sampath TK; Morton RA
Cancer Res; 2000 Jun; 60(11):2840-4. PubMed ID: 10850425
[TBL] [Abstract][Full Text] [Related]
10. Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder.
Chaffer CL; Dopheide B; McCulloch DR; Lee AB; Moseley JM; Thompson EW; Williams ED
Clin Exp Metastasis; 2005; 22(2):115-25. PubMed ID: 16086232
[TBL] [Abstract][Full Text] [Related]
11. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers.
Chaffer CL; Dopheide B; Savagner P; Thompson EW; Williams ED
Differentiation; 2007 Nov; 75(9):831-42. PubMed ID: 17697126
[TBL] [Abstract][Full Text] [Related]
12. Bone morphogenetic protein-2 suppresses invasiveness of TSU-Pr1 cells with the inhibition of MMP-9 secretion.
Kumagai T; Shimizu T; Takeda K
Anticancer Res; 2006; 26(1A):293-8. PubMed ID: 16475709
[TBL] [Abstract][Full Text] [Related]
13. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages.
Tyagi A; Agarwal C; Harrison G; Glode LM; Agarwal R
Carcinogenesis; 2004 Sep; 25(9):1711-20. PubMed ID: 15117815
[TBL] [Abstract][Full Text] [Related]
14. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
Ye L; Lewis-Russell JM; Davies G; Sanders AJ; Kynaston H; Jiang WG
Int J Oncol; 2007 Feb; 30(2):521-9. PubMed ID: 17203235
[TBL] [Abstract][Full Text] [Related]
16. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
17. Med19 promotes bone metastasis and invasiveness of bladder urothelial carcinoma via bone morphogenetic protein 2.
Wen H; Feng CC; Ding GX; Meng DL; Ding Q; Fang ZJ; Xia GW; Xu G; Jiang HW
Ann Diagn Pathol; 2013 Jun; 17(3):259-64. PubMed ID: 23276457
[TBL] [Abstract][Full Text] [Related]
18. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
19. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic proteins and growth and differentiation factors in the human cornea.
You L; Kruse FE; Pohl J; Völcker HE
Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):296-311. PubMed ID: 9950587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
